Article Sidebar

PDF (Tiếng Việt)
Published: 2026-08-04
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v204i7.5387
Issue
Vol. 204 No. 7 (2026)
Section
Các bài báo
How to Cite
Mai, N. T., Tuyên , N. K., Vũ , Đỗ N., Lan, N. M., Bách, Đỗ D., & Anh, N. T. P. (2026). LDL-C target attainment and associated factors among patients with type 2 diabetes mellitus at Thanh Hoa Endocrinology hospital in 2025. Journal of Medical Research, 204(7), 342-353. https://doi.org/10.52852/tcncyh.v204i7.5387

LDL-C target attainment and associated factors among patients with type 2 diabetes mellitus at Thanh Hoa Endocrinology hospital in 2025

Nguyen Thi Mai, Nguyen Kim Tuyen, Do Nguyen Vu, Nguyen My Lan, Do Doan Bach, Nguyen Thi Phuong Anh

Main Article Content

Abstract

A cross-sectional study was conducted among 162 outpatients with type 2 diabetes mellitus at Thanh Hoa Endocrinology Hospital in 2025 to determine the percentage of low-density lipoprotein cholesterol (LDL-C) target attainment and associated factors. The overall LDL-C target attainment level was 50.6%, with the highest proportion observed in the moderate cardiovascular risk group (55.0%) and the lowest in the very high-risk group (35.0%). Moderate-intensity statins were the most commonly used statin regimen (45.1%), whereas high-intensity statin use remained limited (16.7%) and 34.0% of patients were not receiving statin therapy. Multivariable logistic regression analysis showed that male gender (aOR = 2.23; 95% CI: 1.03 – 4.84), good medication adherence (aOR = 3.09; 95% CI: 1.39 – 6.85), and HbA1c < 7% (aOR = 2.38; 95% CI: 1.01 – 5.63) were independently associated with LDL-C target attainment. These findings suggest that LDL-C control among patients with type 2 diabetes mellitus remains suboptimal, particularly in those at high and very high cardiovascular risk.

Article Details

Keywords

Type 2 diabetes mellitus, LDL-C, target attainment, dyslipidemia, medication adherence

References

1. Ference B, Ginsberg H, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459-2472. doi:10.1093/eurheartj/ehx144.
2. Bonilha I, Hajduch E, Luchiari B, Nadruz W, Le Goff W, Sposito A. The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. Metabolites. 2021; 11(12): 807. doi:10.3390/metabo11120807.
3. Mach F, Koskinas K, Roeters van Lennep J, Casula M. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025; 46(42): 4359-4378. doi:10.1093/eurheartj/ehaf190.
4. American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online 2026. doi:10.1161/CIR.0000000000001423
5. Alfadda A, Youssef A, Al-Sofiani M, et al. Medication adherence and treatment satisfaction with lipid-lowering drugs among patients with diabetes and dyslipidemia. Ann Pharmacother. 2025; 59(2): 105-116. doi:10.1177/10600280241262513.
6. Nguyen H, Ha K, Nguyen A, Nguyen T, Lam H. Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam. Ann Geriatr Med Res. 2021; 25(4): 278-285. doi:10.4235/agmr.21.0099.
7. Huỳnh Lê Gia Bảo, Ngô Văn Truyền, Phan Hữu Hên. Nghiên cứu tỷ lệ đạt mục tiêu LDL-C và một số yếu tố liên quan ở bệnh nhân đái tháo đường típ 2 nguy cơ rất cao tại Bệnh viện Trường Đại học Y dược Cần Thơ 2023-2024. Tạp chí Y Dược học Cần Thơ. 2024; (77): 155-161. doi:10.58490/ctump.2024i77.2633.
8. Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020; 41(1): 111-188.
9. Mapi Research Trust. Morisky Medication Adherence Scale-8 item. ePROVIDE - Mapi Research Trust. October 26, 2025. Accessed February 21, 2026. https://eprovide.mapi-trust.org/instruments/morisky-medication-adherence-scale-8-item.
10. Lê Thị Lan Anh, Vũ Bích Nga. Thực trạng điều trị rối loạn lipid máu theo phân tầng nguy cơ tim mạch ở bệnh nhân đái tháo đường típ 2 tại Bệnh viện Đại học Y Hà Nội. Tạp chí Đái tháo đường và Nội tiết Việt Nam. 2023; (66): 56-62.
11. Daovieng Douangchaleun, Nguyễn Quang Bảy. Thực trạng điều trị rối loạn lipid máu ở người bệnh đái tháo đường typ 2 tại phòng khám ngoại trú khoa Nội tiết, Bệnh viện Bạch Mai. Tạp chí Y học Việt Nam. 2024; 542(3). doi:10.51298/vmj.v542i3.11217.
12. Cannon C, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387-2397.
13. Anagnostis P, et al. Menopause-associated dyslipidaemia and cardiovascular risk: More than an adverse lipid profile. Maturitas. 2015; 82(1): 91-103.
14. Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015; 58(5): 862-872.